Effective in non-small-cell lung cancer when added to surgery alone or surgery plus radiotherapy-- Jeff Muise
Thursday, March 25, 2010 (Last Updated: 03/26/2010)
THURSDAY, March 25 (HealthDay News) -- Adding adjuvant chemotherapy to surgery alone or surgery plus radiotherapy improves survival modestly among patients with non-small-cell lung cancer (NSCLC), according to a pair of meta-analyses published online March 24 in The Lancet.
The NSCLC Meta-analyses Collaborative Group carried out separate meta-analyses of trials studying different approaches to adjuvant therapy for NSCLC. The first meta-analysis of 34 clinical trials covering 8,447 subjects compared surgery plus adjuvant chemotherapy to surgery alone. The second meta-analysis of 13 trials covering 2,660 subjects compared surgery plus adjuvant radiotherapy and chemotherapy to surgery plus adjuvant radiotherapy. The researchers compared survival at five years.
In the first meta-analysis, the researchers found that adding adjuvant chemotherapy to surgery resulted in a 4 percent increase in survival at five years (60 to 64 percent), while in the second meta-analysis, adding chemotherapy to surgery and radiotherapy also resulted in a 4 percent increase in survival at five years (29 to 33 percent). These effects did not vary significantly by type of chemotherapy or patient subgroup.
"The addition of adjuvant chemotherapy after surgery for patients with operable NSCLC improves survival, irrespective of whether chemotherapy was adjuvant to surgery alone or adjuvant to surgery plus radiotherapy," the authors write.
Funding for the study was provided in part by Sanofi-Aventis.
OBGYN & Women's Health
Copyright © 2010 HealthDay. All rights reserved.